Analysts Set Henry Schein, Inc. (NASDAQ:HSIC) Price Target at $87.75

Shares of Henry Schein, Inc. (NASDAQ:HSIC) have been assigned an average rating of “Hold” from the fourteen ratings firms that are covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating, seven have given a hold rating and six have issued a buy rating on the company. The average twelve-month target price among brokerages that have issued a report on the stock in the last year is $86.8333.

Several brokerages have recently issued reports on HSIC. Robert W. Baird set a $97.00 price target on Henry Schein in a research report on Wednesday. Citigroup began coverage on Henry Schein in a research report on Wednesday, April 15th. They issued a “buy” rating and a $100.00 price target on the stock. UBS Group reaffirmed a “neutral” rating and issued a $85.00 price target (down from $87.00) on shares of Henry Schein in a research report on Wednesday. Leerink Partners reaffirmed a “market perform” rating on shares of Henry Schein in a research report on Monday, March 9th. Finally, Wells Fargo & Company raised their price target on Henry Schein from $76.00 to $87.00 and gave the company an “equal weight” rating in a research report on Wednesday, February 25th.

Henry Schein Price Performance

NASDAQ HSIC opened at $70.50 on Friday. Henry Schein has a fifty-two week low of $61.94 and a fifty-two week high of $89.29. The stock’s 50-day moving average is $76.06 and its two-hundred day moving average is $75.05. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.36 and a quick ratio of 0.76. The firm has a market cap of $8.09 billion, a P/E ratio of 21.30, a price-to-earnings-growth ratio of 1.82 and a beta of 0.82.

Henry Schein (NASDAQ:HSIC) last posted its earnings results on Tuesday, May 5th. The company reported $1.32 earnings per share for the quarter, beating the consensus estimate of $1.20 by $0.12. Henry Schein had a return on equity of 15.44% and a net margin of 2.95%.The company had revenue of $3.37 billion for the quarter, compared to analyst estimates of $3.34 billion. During the same period last year, the company earned $1.15 earnings per share. The business’s revenue was up 6.3% compared to the same quarter last year. Henry Schein has set its FY 2026 guidance at 5.230-5.370 EPS. On average, analysts anticipate that Henry Schein will post 5.31 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, Director Philip A. Laskawy sold 2,844 shares of Henry Schein stock in a transaction dated Thursday, March 5th. The stock was sold at an average price of $80.36, for a total transaction of $228,543.84. Following the sale, the director directly owned 21,961 shares of the company’s stock, valued at $1,764,785.96. This trade represents a 11.47% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Mark E. Mlotek sold 5,925 shares of Henry Schein stock in a transaction dated Wednesday, March 4th. The stock was sold at an average price of $80.80, for a total value of $478,740.00. Following the sale, the executive vice president directly owned 80,554 shares in the company, valued at approximately $6,508,763.20. This trade represents a 6.85% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 105,911 shares of company stock valued at $8,574,982 in the last quarter. Insiders own 0.89% of the company’s stock.

Institutional Investors Weigh In On Henry Schein

A number of institutional investors have recently added to or reduced their stakes in HSIC. MAI Capital Management boosted its holdings in Henry Schein by 7.5% during the third quarter. MAI Capital Management now owns 2,061 shares of the company’s stock valued at $137,000 after purchasing an additional 144 shares in the last quarter. Parallel Advisors LLC boosted its holdings in Henry Schein by 12.7% during the first quarter. Parallel Advisors LLC now owns 1,314 shares of the company’s stock valued at $97,000 after purchasing an additional 148 shares in the last quarter. Truist Financial Corp boosted its holdings in Henry Schein by 3.3% during the third quarter. Truist Financial Corp now owns 5,540 shares of the company’s stock valued at $368,000 after purchasing an additional 175 shares in the last quarter. HB Wealth Management LLC boosted its holdings in Henry Schein by 1.3% during the fourth quarter. HB Wealth Management LLC now owns 15,034 shares of the company’s stock valued at $1,136,000 after purchasing an additional 191 shares in the last quarter. Finally, Czech National Bank boosted its holdings in Henry Schein by 0.8% during the fourth quarter. Czech National Bank now owns 26,386 shares of the company’s stock valued at $1,994,000 after purchasing an additional 206 shares in the last quarter. 96.62% of the stock is owned by institutional investors and hedge funds.

About Henry Schein

Henry Schein, Inc is a leading global distributor of healthcare products and services, primarily serving office-based dental, medical and animal health practitioners. The company operates through three principal segments—Schein Dental, Schein Medical and Animal Health—each offering a comprehensive portfolio of consumable products, equipment, instruments and related value-added services. With a focus on improving practice efficiency and patient care, Henry Schein provides everything from dental restorative materials and orthodontic appliances to vaccines, pharmaceuticals and diagnostic devices for physicians, as well as pet health products and veterinary equipment for animal health professionals.

In addition to its broad product offering, Henry Schein delivers a suite of technology and service solutions aimed at streamlining workflows and enhancing clinical outcomes.